• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血液透析患者血清磷变异性与冠状动脉钙化的关联

Association of serum phosphorus variability with coronary artery calcification among hemodialysis patients.

作者信息

Wang Mengjing, Li Haiming, You Li, Yu Xiaoling, Zhang Min, Zhu Ruijiang, Hao Chuanming, Zhang Zhijie, Chen Jing

机构信息

Division of Nephrology, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.

Division of Radiology, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.

出版信息

PLoS One. 2014 Apr 18;9(4):e93360. doi: 10.1371/journal.pone.0093360. eCollection 2014.

DOI:10.1371/journal.pone.0093360
PMID:24747427
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3991577/
Abstract

Coronary artery calcification (CAC) is associated with increased mortality in patients on maintenance hemodialysis (MHD), but the pathogenesis of this condition is not well understood. We evaluated the relationship of CAC score (CACs) and variability in serum phosphorus in MHD patients. Seventy-seven adults on MHD at Huashan Hospital (Shanghai) were enrolled in July, 2010. CAC of all the patients were measured by computed tomography and CACs was calculated by the Agatston method at the entry of enrollment. Patients were divided into three categories according to their CACs (0∼10, 11∼400, and >400). Blood chemistry was recorded every 3 months from January 2008 to July 2010. Phosphorus variation was defined by the standard deviation (SD) or coefficient of variation (CV) and it was calculated from the past records. The ordinal multivariate logistic regression analysis was used to analyze the predictors of CAC. The mean patient age (± SD) was 61.7 years (±11.3) and 51% of patients were men. The mean CACs was 609.6 (±1062.9), the median CACs was 168.5, and 78% of patients had CACs more than 0. Multivariate analysis indicated that female gender (OR = 0.20, 95% CI = 0.07-0.55), age (OR = 2.31, 95% CI = 1.32-4.04), serum fibroblast growth factor 23 (OR = 2.25, 95% CI = 1.31-3.85), SD-phosphorus calculated from the most recent 6 measurements (OR = 2.12; 95% CI = 1.23-3.63), and CV-phosphorus calculated from the most recent 6 measurements (OR = 1.90, 95% CI = 1.16-3.11) were significantly and independently associated with CACs. These associations persisted for phosphorus variation calculated from past 7, 8, 9, 10, and 11 follow-up values. Variability of serum phosphorus may contribute significantly to CAC and keeping serum phosphorus stable may decrease coronary calcification and associated morbidity and mortality in MHD patients.

摘要

冠状动脉钙化(CAC)与维持性血液透析(MHD)患者死亡率增加相关,但这种情况的发病机制尚不清楚。我们评估了MHD患者中CAC评分(CACs)与血清磷变异性之间的关系。2010年7月,纳入了上海华山医院77例接受MHD治疗的成年人。在入组时,通过计算机断层扫描测量所有患者的CAC,并采用阿加斯顿法计算CACs。根据患者的CACs(0至10、11至400和>400)将其分为三类。从2008年1月至2010年7月,每3个月记录一次血液生化指标。磷变异通过标准差(SD)或变异系数(CV)定义,并根据既往记录计算得出。采用有序多变量逻辑回归分析来分析CAC的预测因素。患者的平均年龄(±标准差)为61.7岁(±11.3),51%为男性。平均CACs为609.6(±1062.9),中位数CACs为168.5,78%的患者CACs大于0。多变量分析表明,女性(比值比[OR]=0.20,95%置信区间[CI]=0.07 - 0.55)、年龄(OR=2.31,95% CI=1.32 - 4.04)、血清成纤维细胞生长因子23(OR=2.25,95% CI=1.31 - 3.85)、根据最近6次测量计算的SD-磷(OR=2.12;95% CI=1.23 - 3.63)以及根据最近6次测量计算的CV-磷(OR=1.90,95% CI=1.16 - 3.11)与CACs显著且独立相关。这些关联在根据过去7、8、9、10和11次随访值计算的磷变异中持续存在。血清磷的变异性可能对CAC有显著影响,保持血清磷稳定可能降低MHD患者的冠状动脉钙化及相关发病率和死亡率。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4545/3991577/af9d7ca0a979/pone.0093360.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4545/3991577/e4f5aa31f91f/pone.0093360.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4545/3991577/1f1beba9bda4/pone.0093360.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4545/3991577/af9d7ca0a979/pone.0093360.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4545/3991577/e4f5aa31f91f/pone.0093360.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4545/3991577/1f1beba9bda4/pone.0093360.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4545/3991577/af9d7ca0a979/pone.0093360.g003.jpg

相似文献

1
Association of serum phosphorus variability with coronary artery calcification among hemodialysis patients.血液透析患者血清磷变异性与冠状动脉钙化的关联
PLoS One. 2014 Apr 18;9(4):e93360. doi: 10.1371/journal.pone.0093360. eCollection 2014.
2
The relationship between coronary artery calcification and bone metabolic markers in maintenance hemodialysis patients.维持性血液透析患者冠状动脉钙化与骨代谢标志物的关系。
BMC Nephrol. 2023 Aug 15;24(1):238. doi: 10.1186/s12882-023-03286-z.
3
[Risk factors for coronary artery calcification in patients with end-stage renal disease].[终末期肾病患者冠状动脉钙化的危险因素]
Zhonghua Yi Xue Za Zhi. 2015 Oct 13;95(38):3133-7.
4
Serum S100A12 and Progression of Coronary Artery Calcification Over 4 Years in Hemodialysis Patients.血液透析患者血清S100A12与4年冠状动脉钙化进展情况
Am J Nephrol. 2015;42(1):4-13. doi: 10.1159/000438869. Epub 2015 Aug 13.
5
Correlation of coronary artery calcification with pre-hemodialysis bicarbonate levels in patients on hemodialysis.血液透析患者冠状动脉钙化与透析前碳酸氢盐水平的相关性
Ther Apher Dial. 2012 Jun;16(3):267-71. doi: 10.1111/j.1744-9987.2011.01054.x. Epub 2012 Mar 5.
6
FGF-23 associated with the progression of coronary artery calcification in hemodialysis patients.成纤维细胞生长因子 23 与血液透析患者冠状动脉钙化进展相关。
BMC Nephrol. 2013 Nov 1;14:241. doi: 10.1186/1471-2369-14-241.
7
Effect of serum FGF-23, MGP and fetuin-A on calcium-phosphate metabolism in maintenance hemodialysis patients.血清成纤维细胞生长因子-23、基质Gla蛋白和胎球蛋白-A对维持性血液透析患者钙磷代谢的影响
Hemodial Int. 2013 Oct;17(4):483-92. doi: 10.1111/hdi.12033. Epub 2013 Mar 12.
8
Association Between Angiotensin-Converting Enzyme 2 and Coronary Artery Calcification in Patients on Maintenance Hemodialysis Therapy.维持性血液透析治疗患者中血管紧张素转换酶2与冠状动脉钙化的关联
Ther Apher Dial. 2015 Oct;19(5):466-70. doi: 10.1111/1744-9987.12298. Epub 2015 Jun 25.
9
FGF-23 and the progression of coronary arterial calcification in patients new to dialysis.成纤维细胞生长因子 23 与新透析患者冠状动脉钙化的进展。
Clin J Am Soc Nephrol. 2012 Dec;7(12):2017-22. doi: 10.2215/CJN.02160212. Epub 2012 Sep 20.
10
Association of serum alkaline phosphatase with coronary artery calcification in maintenance hemodialysis patients.维持性血液透析患者血清碱性磷酸酶与冠状动脉钙化的相关性
Clin J Am Soc Nephrol. 2009 Jun;4(6):1106-14. doi: 10.2215/CJN.06091108. Epub 2009 May 7.

引用本文的文献

1
Impact of Phosphate Variability in Patients Undergoing Hemodialysis.血液透析患者中磷酸盐变异性的影响
Nutrients. 2025 Apr 30;17(9):1528. doi: 10.3390/nu17091528.
2
Pathophysiology and Clinical Impacts of Chronic Kidney Disease on Coronary Artery Calcification.慢性肾脏病对冠状动脉钙化的病理生理学及临床影响
J Cardiovasc Dev Dis. 2023 May 10;10(5):207. doi: 10.3390/jcdd10050207.
3
Focusing on Phosphorus Loads: From Healthy People to Chronic Kidney Disease.聚焦磷负荷:从健康人群到慢性肾脏病。

本文引用的文献

1
Calcification of coronary arteries and abdominal aorta in relation to traditional and novel risk factors of atherosclerosis in hemodialysis patients.血液透析患者冠状动脉和腹主动脉钙化与动脉粥样硬化传统和新型危险因素的关系。
BMC Nephrol. 2013 Jan 14;14:10. doi: 10.1186/1471-2369-14-10.
2
A preliminary study of the potential role of FGF-23 in coronary calcification in patients with suspected coronary artery disease.成纤维细胞生长因子 23 在疑似冠心病患者冠状动脉钙化中作用的初步研究。
Atherosclerosis. 2013 Jan;226(1):228-33. doi: 10.1016/j.atherosclerosis.2012.10.045. Epub 2012 Oct 24.
3
Association of circulating fibroblast growth factor-23 with renal phosphate excretion among hemodialysis patients with residual renal function.
Nutrients. 2023 Feb 28;15(5):1236. doi: 10.3390/nu15051236.
4
Gender-Related Differences in Chronic Kidney Disease-Associated Vascular Calcification Risk and Potential Risk Mediators: A Scoping Review.慢性肾脏病相关血管钙化风险及潜在风险介导因素的性别差异:一项范围综述
Healthcare (Basel). 2021 Aug 1;9(8):979. doi: 10.3390/healthcare9080979.
维持性血液透析患者残余肾功能与循环成纤维细胞生长因子 23 对磷排泄的影响。
Clin J Am Soc Nephrol. 2013 Jan;8(1):116-25. doi: 10.2215/CJN.00230112. Epub 2012 Oct 18.
4
FGF-23 and the progression of coronary arterial calcification in patients new to dialysis.成纤维细胞生长因子 23 与新透析患者冠状动脉钙化的进展。
Clin J Am Soc Nephrol. 2012 Dec;7(12):2017-22. doi: 10.2215/CJN.02160212. Epub 2012 Sep 20.
5
Increased levels of serum parathyroid hormone and fibroblast growth factor-23 are the main factors associated with the progression of vascular calcification in long-hour hemodialysis patients.血清甲状旁腺激素和成纤维细胞生长因子 23 水平升高是与长时血液透析患者血管钙化进展相关的主要因素。
Nephron Clin Pract. 2012;120(3):c132-8. doi: 10.1159/000334424. Epub 2012 May 11.
6
Vascular Klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23.血管 Klotho 缺乏会增强人动脉钙化的发展,并介导对成纤维细胞生长因子 23 的抵抗。
Circulation. 2012 May 8;125(18):2243-55. doi: 10.1161/CIRCULATIONAHA.111.053405. Epub 2012 Apr 5.
7
Osteoprotegerin/RANKL axis and progression of coronary artery calcification in hemodialysis patients.骨保护素/RANKL 轴与血液透析患者冠状动脉钙化进展。
Clin J Am Soc Nephrol. 2012 Jun;7(6):965-73. doi: 10.2215/CJN.11191111. Epub 2012 Apr 5.
8
FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages.成纤维细胞生长因子 23 与血管钙化相关,但与不同 CKD 分期患者的骨密度无关。
Osteoporos Int. 2012 Jul;23(7):2017-25. doi: 10.1007/s00198-011-1838-0. Epub 2011 Nov 23.
9
Vascular calcification in patients with chronic kidney disease.慢性肾病患者的血管钙化
Ther Apher Dial. 2011 Dec;15(6):513-21. doi: 10.1111/j.1744-9987.2011.00979.x. Epub 2011 Sep 9.
10
Fibroblast growth factor 23 and the bone-vascular axis: lessons learned from animal studies.成纤维细胞生长因子 23 与骨-血管轴:动物研究中的经验教训。
Am J Kidney Dis. 2012 Jan;59(1):135-44. doi: 10.1053/j.ajkd.2011.07.027. Epub 2011 Nov 8.